Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Renal Pelvis and Ureter Urothelial Carcinoma 1

Interventions

Cisplatin 14Carboplatin 12Magnetic Resonance Spectroscopy 11Specimen Handling 10Gemcitabine 10pembrolizumab 8Pemetrexed 8atezolizumab 7Paclitaxel 7Radiotherapy, Intensity-Modulated 5Platinum 5Nivolumab 5Immunoglobulin G 5Doxorubicin 5Docetaxel 5Disulfides 5Bevacizumab 5130-nm albumin-bound paclitaxel 51,2-diaminocyclohexaneplatinum II citrate 5Cetuximab 4Biopsy 4durvalumab 3Temozolomide 3Standard of Care 3Rituximab 3Drug Therapy 3Dexamethasone 3Cyclophosphamide 3(225)Ac-DOTA-c(RGDyK) 3venetoclax 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Vinblastine × 30 days × Clear all
NCT04628767 2026-06-03

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
131 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡